Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
NCT06100874
Recruiting
This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: * Sacituzumab govitecan (a type of antibody-drug conjugate) * Trastuzumab (Herceptin) (a type of monoclonal antibody) * Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) * Trast... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Dana Farber Cancer Institite, Boston, Massachusetts
Conditions: Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
Register for Updates
Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC
NCT05881304
Recruiting
The goal of this study is to conduct a pilot randomized waitlist-controlled trial to assess the feasibility, acceptability, and preliminary effects of substituting the NIDA standardized research e-cigarette (SREC) for combusted cigarettes in MOUD-TUD who are not ready to quit smoking. A waitlist controlled RCT using a mixed-methods sequential explanatory design will investigate the impact of SREC provision on: 1) tobacco use behavior (e.g., cigarettes per day \[primary outcome\], SREC use), 2) b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Electronic Cigarette Use
Register for Updates
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
NCT05848739
Recruiting
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Colon Cancer, Metastatic Colon Cancer
Register for Updates
Enhancing Modulation Effects of Baduanjin Through Neuromodulation for Knee OA
NCT05839535
Recruiting
This study will combine brain imaging and neuromodulation tools to investigate the underlying neurobiological mechanisms of exercises. The findings will enhance our understanding of the mechanisms underlying mind-body exercise and facilitate the development of new pain management approaches.
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Charlestown, Massachusetts
Conditions: Knee Osteoarthritis
Register for Updates
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
NCT05831111
Recruiting
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/06/2025
Locations: DM Clinical Research, Brookline, Massachusetts
Conditions: Epstein-Barr Virus Infection
Register for Updates
Avatrombopag vs. Placebo for CIT in GI Malignancies
NCT05772546
Recruiting
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: * Avatrombopag (a thrombopoietin receptor agonist) * Matching placebo
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Register for Updates
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
NCT05630963
Recruiting
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/06/2025
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
NCT05417776
Recruiting
The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Interstitial Lung Disease
Register for Updates
Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage
NCT05103566
Recruiting
This is a single-site, single-arm, open-label pilot study assessing the safety, feasibility, and efficacy of non-invasive vagus nerve stimulation (nVNS), gammaCore, for the acute treatment of aneurysmal subarachnoid hemorrhage (SAH) subjects in a neurocritical care setting. 25 patients will be enrolled, all treated with an active device. The primary efficacy outcomes are reduced aneurysm rupture rate, reduced seizure and seizure-spectrum activity, minimized hemorrhage grades, and increased survi... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Subarachnoid Hemorrhage, Aneurysmal
Register for Updates
Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)
NCT04895306
Recruiting
The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, physical function and quality of life when compared with placebo in women with chronic back pain treated with opioids who have low testosterone.
Gender:
FEMALE
Ages:
60 years and above
Trial Updated:
05/06/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Pain, Opioid Use, Androgen Deficiency, Back Pain
Register for Updates
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NCT04838301
Recruiting
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
05/06/2025
Locations: MedVadis Research, Waltham, Massachusetts
Conditions: Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
Register for Updates
Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations
NCT04612738
Recruiting
Compared to the general population, individuals from underserved communities are more likely to receive low quality end-of-life care and unwanted, costly and burdensome treatments due in part to a lack of advance care planning (ACP; the process of discussing wishes for end-of-life care with loved ones/clinicians and documenting them in advance directives). This study will use existing, trusted, and respected social networks to evaluate two conversation-based tools intended to engage underserved... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Grove Hall Senior Center, Boston, Massachusetts
Conditions: Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
Register for Updates